A variety of chemotherapy regimens are available for acute myeloid leukemia II. Fludarabine, nitrogen mustard phenylbutyrate tablets monotherapy, cyclophosphamide combined with rituximab, therapeutic regimens and anti-CD52 monoclonal antibodies are among the regimens available.
Acute myeloid leukemia, which can manifest with clinical symptoms such as bleeding, anemia, fever and infection, and leukemic cell infiltration. Patients with acute myeloid leukemia have varying degrees of bleeding, especially in the mouth, nose, and gums, and some have fundus bulbar conjunctival hemorrhage and hematuria. In severe cases, respiratory and gastrointestinal as well as intracranial bleeding may also occur. However, any infection is also more common, with irregular fever. As well as the appearance of infection in the body and body surface.
Manifestations of leukemic cell infiltration, oral gingival changes and skin infiltration, as well as bone and joint pain and dry skin lymphomegaly, central nervous system involvement, and ocular symptoms.
The skin may appear maculopapular and nodular with a purple color appearance. The gums of the mouth may appear swollen and bleed from ruptured ulcers. The spleen and liver lymph nodes are enlarged, the bones are painful, and there is central nervous involvement and seizures such as convulsions and paralysis. The eye disease can cause blindness or diplopia and protrusion of the eye.